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The	limited	effectiveness	of	rituximab	plus	intravenous	immunoglobulin	(IVIG)	in	desen‐
sitization	may	be	due	to	 incomplete	B	cell	depletion.	Obinutuzumab	 is	a	 type	2	anti‐
CD20	antibody	that	 induces	 increased	B	cell	depletion	relative	 to	 rituximab	and	may	
therefore	be	more	effective	for	desensitization.	This	open‐label	phase	1b	study	assessed	
the	safety,	pharmacokinetics,	and	pharmacodynamics	of	obinutuzumab	in	highly	sensi‐
tized	patients	with	end‐stage	renal	disease.	Patients	received	1	(day	1,	n	=	5)	or	2	(days	1	
and	15;	n	=	20)	infusions	of	1000‐mg	obinutuzumab	followed	by	2	doses	of	IVIG	on	days	
22	and	43.	Eleven	patients	received	additional	obinutuzumab	doses	at	the	time	of	trans‐
plant	and/or	at	week	24.	The	median	follow‐up	duration	was	9.4	months.	Obinutuzumab	
was	well	tolerated,	and	most	adverse	events	were	grade	1‐2	in	severity.	There	were	11	
serious	adverse	events	(SAEs)	in	9	patients	(36%);	10	of	these	SAEs	were	infections	and	
4	occurred	after	kidney	transplant.	Obinutuzumab	plus	IVIG	resulted	in	profound	pe‐
ripheral	B	cell	depletion	and	appeared	to	reduce	B	cells	in	retroperitoneal	lymph	nodes.	
Reductions	in	anti‐HLA	antibodies,	number	of	unacceptable	antigens,	and	the	calculated	
panel	reactive	antibody	score	as	centrally	assessed	using	single‐antigen	bead	assay	were	
limited	and	not	clinically	meaningful	for	most	patients	(NCT02586051).
K E Y W O R D S
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modulation,	kidney	transplantation/nephrology,	pharmacology
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1  | INTRODUC TION
Antihuman	leukocyte	antigen	(HLA)	alloantibodies	are	a	major	bar‐
rier	to	successful	kidney	transplantation	in	patients	with	end‐stage	
renal	disease	(ESRD)	and	can	lead	to	substantial	reductions	in	renal	
allograft	 survival.1,2	 HLA‐sensitized	 patients	 represent	 approxi‐
mately	 30%	of	 patients	 on	 the	waitlist	 for	 kidney	 transplant3 and 
historically	have	faced	longer	wait	times	for	a	suitable	donor	graft—
as	well	as	inferior	long‐term	outcomes	following	transplant—than	pa‐
tients	who	are	not	sensitized.4‐6	To	improve	access	to	transplant	for	
this	population,	several	approaches	have	been	attempted,	including	
treatment	with	the	anti‐CD20	monoclonal	antibody	rituximab	to	de‐
plete	CD20+	B	cells,	which	play	a	central	role	in	humoral	immunity.
A	 seminal	 study	 combining	 rituximab	 with	 intravenous	 immu‐
noglobulin	(IVIG)	reported	reduction	of	the	level	of	sensitization	(as	
measured	by	panel	reactive	antibodies	[PRA])	that	enabled	most	pa‐
tients	(16/20;	80%)	to	receive	a	kidney	graft	with	excellent	posttrans‐
plant	outcomes.7	 These	effects	were	not	 replicated	 in	 subsequent	
similarly	 uncontrolled	 case	 series,	 however,	 raising	 the	 question	
whether	inconsistent	effects	might	be	due	to	the	patient	populations	
studied.	Alternatively,	this	could	be	due	to	incomplete	tissue	B	cell	
depletion.8‐12	 B	 cell	 depletion	 would	 be	 expected	 to	 reduce	 anti‐
HLA	 alloantibody	 levels	 if	 anti‐HLA	 alloantibodies	were	 produced	
by	a	plasma‐cell	population	that	required	ongoing	replenishment	by	
production	 of	 new	 plasmablasts	 from	memory	 B	 cell	 populations.	
Despite	enabling	peripheral	blood	B	cell	depletion,	rituximab	incom‐
pletely	 depletes	 lymphoid	 organ	 B	 cells.8,11‐13	 Although	 the	 exact	
reasons	for	the	inconsistent	effects	of	rituximab	on	desensitization	
are	not	known,	one	hypothesis	is	that	achieving	more	extensive	B	cell	
depletion	than	is	achieved	with	rituximab,	particularly	in	tissue,	may	
improve	results	in	highly	sensitized	patients	with	ESRD.
Obinutuzumab	is	a	glycoengineered	type	2	anti‐CD20	monoclonal	
antibody	that	has	been	shown	to	be	more	efficacious	than	rituximab	in	
depleting	B	cells	in	peripheral	blood	and	lymphoid	tissue,	in	both	ani‐
mal	models	and	patients	with	chronic	lymphocytic	leukemia	(CLL);13,14 
in	particular,	significantly	greater	B	cell	depletion	in	bone	marrow	was	
observed	 with	 obinutuzumab	 than	 with	 rituximab	 in	 patients	 with	
CLL.14	We	hypothesized	that	 the	greater	capacity	of	obinutuzumab	
to	induce	depletion	of	tissue‐resident	B	cells	may	overcome	the	lim‐
itations	of	rituximab	and	provide	greater	anti‐HLA	antibody	reduction	
in	highly	sensitized	patients.	We	present	here	the	results	of	an	open‐
label	study	of	obinutuzumab	in	combination	with	high‐dose	IVIG	to	
evaluate	the	safety,	tolerability,	and	pharmacokinetics	(PK)	of	obinu‐
tuzumab	and	its	effect	on	B	cell	depletion	and	anti‐HLA	antibodies	in	
highly	sensitized	patients	with	ESRD	awaiting	transplant.
2  | MATERIAL S AND METHODS
2.1 | Study design
THEORY	 was	 a	 phase	 1b,	 open‐label,	 sequential	 2‐cohort	 study	
comparing	 single	 and	 repeated	 doses	 of	 obinutuzumab	 with	
high‐dose	IVIG	in	highly	sensitized	candidates	for	renal	transplant	
in	 the	 United	 States	 (NCT02586051).	 Twenty‐five	 patients	 were	
enrolled	between	November	2015	and	August	2016	at	7	 centers	
in	 the	United	States.	Patients	 in	 cohort	1	 received	a	 single	 intra‐
venous	 infusion	of	1000‐mg	obinutuzumab	on	day	1	 followed	by	
2	g/kg	IVIG	(maximum	140	g)	at	weeks	3	and	6.	Following	a	28‐day	
observation	period	for	adverse	events	(AEs),	patients	were	enrolled	
in	cohort	2	and	received	1000‐mg	obinutuzumab	infusions	on	days	
1	 and	15,	 and	 an	 optional	 1000‐mg	 infusion	 at	week	24,	 plus	 an	
IVIG	regimen	identical	to	cohort	1.	All	patients	were	monitored	for	
12	 months	 following	 the	 last	 obinutuzumab	 infusion	 (Figure	 S1).	
Patients	who	underwent	kidney	 transplant	 (per	 local	center	prac‐
tices)	before	week	52	received	an	additional	obinutuzumab	infusion	
at	the	time	of	transplant	(peritransplant)	and	24	weeks	after	trans‐
plant	and	were	followed	up	for	52	weeks	after	their	 last	obinutu‐
zumab	dose	to	further	assess	safety	and	tolerability.	The	transplant	
population	is	still	being	followed	at	the	time	of	this	report	and	will	
be	described	separately.	Analyses	are	based	on	the	data	available	as	
of	March	10,	2017,	unless	otherwise	stated.	Statistical	methods	are	
described	in	the	Data	S1.
This	study	was	conducted	in	accordance	with	local	institutional	
review	 board	 ethical	 standards,	 good	 clinical	 practices,	 and	 the	
Declaration	of	Helsinki.	All	patients	provided	written	informed	con‐
sent	before	study	participation.
2.2 | Study objectives
The	 primary	 objective	 assessed	 the	 safety	 and	 tolerability	 of	
the	 obinutuzumab/IVIG	 regimen	 at	 week	 24	 of	 the	 desensitiza‐
tion	 phase.	 The	 secondary	 objective	 characterized	 the	 PK	 and	
pharmacodynamic	 (PD)	profiles	of	obinutuzumab.	PD	markers	 in‐
cluded	peripheral	blood	CD19+	B	cells	and	anti‐HLA	alloantibodies.	
Exploratory	 objectives	 aimed	 to	 quantify	 the	 impact	 of	 obinutu‐
zumab	on	sensitization	as	measured	by	the	number	of	unaccepta‐
ble	antigens	 (UAs),	 the	calculated	panel	reactive	antibody	 (CPRA)	
score,	 and	 anti‐HLA	 antibodies	 strength	 at	 week	 24,	 as	 well	 as	
posttransplant	 estimated	 glomerular	 filtration	 rate	 (eGFR),	 calcu‐
lated	 using	 Chronic	 Kidney	 Disease	 Epidemiology	 Collaboration	
equation.15
2.3 | Patient selection
Patients	were	18‐65	years	old,	had	ESRD,	were	awaiting	renal	trans‐
plant,	and	had	both	a	history	of	sensitizing	events	and	CPRA	≥	50%	
at	 screening.	 CPRA	was	 calculated	 based	 on	 input	 from	 the	 local	
transplant	 team	 and	 incorporated	 site‐generated	 data	 (Data	 S1).	
Patients	 were	 required	 to	 be	 United	 Network	 for	 Organ	 Sharing	
listed	for	a	deceased	donor	kidney	transplant	and	have	an	estimated	
high	likelihood	of	receiving	an	offer	12‐18	months	after	screening,	as	
evidenced	by	presence	on	≥1	match	run	for	a	deceased	donor	kidney	
during	 the	past	year	or	CPRA	≥98%.	The	number	of	patients	who	
had	received	a	prior	transplant	was	capped	at	6.	Further	details	are	
available	in	the	Data	S1.
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2.4 | Blood B cell enumeration and measurement 
in tissue
B	cells	were	measured	using	a	validated	6‐color,	lyse/no‐wash	flow	
cytometry	assay.	Cells	from	peripheral	blood	or	lymph	nodes	were	
stained	with	antibodies	to	identify	B	cells.	Total	B	cells	were	defined	
using	 light	 scatter	 characteristics,	 CD45+,	 CD3−/CD14−,	 CD56−/
CD33−,	and	CD19+.	Further	details	are	available	in	the	Data	S1.
2.5 | Anti‐HLA antibodies
For	patient	clinical	management,	participating	sites	continued	to	use	
antibody	screening	data	generated	at	their	local	laboratories.	Serum	
samples	were	collected	 in	parallel	for	central	study	analyses.	Anti‐
HLA	 alloantibodies	 were	 quantified	 using	 Luminex‐based	 single‐	
antigen	bead	(SAB)	Lab	Screen	assays	at	the	UCLA	Immunogenetics	
Center	 (Clinical	 Laboratory	 Improvement	 Amendments	 certified	
and	American	 Society	 for	Histocompatibility	 and	 Immunogenetics	
accredited).	Anti‐HLA	serum	reactivity	was	calculated	by	measure‐
ment	of	HLA	antibody	bound	to	each	bead,	expressed	as	mean	fluo‐
rescence	intensity	(MFI).16	The	desensitization	assessment	scientific	
panel	and	criteria	for	UAs	are	described	in	the	Data	S1.
2.6 | Laboratory assessments
All	 laboratory	 safety	 assessments,	 including	 IgA,	 IgM,	 IgG,	 vac‐
cination	 titers,	 and	 the	 schedule	 of	 assessments,	 are	 depicted	 in	
Tables	S1	and	S2.
3  | RESULTS
3.1 | Patient disposition and baseline characteristics
Twenty‐five	patients	were	enrolled	and	received	≥1	dose	of	obinu‐
tuzumab	 (cohort	1,	n	=	5;	cohort	2,	n	=	20).	As	of	 the	data	cutoff	
of	 March	 10,	 2017,	 8	 patients	 had	 received	 a	 transplant	 (cohort	
1,	 n	 =	 1;	 cohort	 2,	 n	 =	 7).	One	 of	 the	 7	 patients	 in	 cohort	 2	was	
withdrawn	before	day	15	because	the	patient	received	a	transplant	
6	days	 after	 the	baseline	visit	 and	 therefore	 received	only	1	dose	
of	 obinutuzumab	 and	 no	 IVIG	 infusion;	 this	 patient	 was	 followed	
for	safety	only	and	not	included	in	the	exploratory	efficacy	assess‐
ment.	Overall,	6	of	the	8	patients	had	received	2	doses	of	obinutu‐
zumab	prior	to	transplantation,	and	the	remaining	2	received	only	1	
dose	each	 (Figure	1).	 Per	protocol,	 patients	undergoing	 transplant	
received	additional	doses	of	obinutuzumab	around	the	time	of	and	
24	weeks	after	renal	transplant.	Patient	baseline	characteristics	are	
presented	in	Table	1.
3.2 | Safety
A	total	of	193	AEs	were	reported	in	22	of	25	patients	(88%).	Of	those	
AEs,	38	occurred	at	a	median	of	0.5	(range,	0‐18)	weeks	after	trans‐
plant	in	the	8	patients	who	had	received	a	transplant.
No	deaths	were	reported.	The	most	common	adverse	drug	re‐
actions	were	nonserious	protocol‐defined	infusion‐related	reactions	
(IRRs)	(Data	S1),	occurring	in	13	patients	(52%).	IRRs	occurred	mainly	
after	 the	 first	 infusion	only,	except	 in	3	patients	who	experienced	
an	IRR	at	both	the	first	and	second	infusions.	No	IRRs	 led	to	dose	
reduction	or	discontinuation;	the	most	common	IRR	symptoms	were	
chills	(5	patients),	nausea	(4	patients),	and	hypotension	(3	patients).
Eleven	 patients	 (44%)	 experienced	 21	 infection	 AEs	 a	median	
(range)	of	9.4	(6.5‐15.6)	weeks	after	the	initial	dose.	Eight	of	those	
21	infections	occurred	after	kidney	transplant	in	3	of	the	8	patients	
who	received	a	transplant.
Eleven	 serious	AEs	 (SAEs)	were	 reported	 in	 9	 patients	 (36%)	
(Table	2);	10	were	 infections	reported	 in	8	patients	 (32%)	with	a	
median	 (range)	 onset	 of	 6	 (4‐34)	weeks	 after	 last	 obinutuzumab	
infusion.	 Four	 of	 the	 10	 infection	 SAEs	 occurred	 after	 kidney	
transplant	in	3	patients;	these	were	pneumonia	and	nocardiosis	in	
1	patient,	incision	infection	in	another,	and	postoperative	wound	
infection	in	a	third	patient.	All	SAEs	resolved	with	standard	med‐
ical	 care,	without	 sequelae.	Of	 the	11	SAEs,	3	 reported	 in	2	pa‐
tients	were	assessed	by	the	investigators	as	related	to	study	drug	
(pneumonia	and	nocardiosis	in	1	patient	and	pneumonia	in	another	
F I G U R E  1  Patient	disposition	and	
number	of	obinutuzumab	(Obi)	doses.	
aThis	patient	received	1	obinutuzumab	
dose	before	transplant	and	1	dose	after.	
bThis patient received a transplant at 
week	1	and	was	withdrawn	from	study	
treatment. cThese 5 patients received 2 
obinutuzumab	doses	before	transplant	
and	1	dose	after.	dThis patient received 
2	obinutuzumab	doses	before	transplant	
and	2	doses	after
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patient).	The	case	of	pneumonia	and	nocardiosis	was	in	a	61‐year‐
old	female	patient,	63	days	after	receiving	a	deceased	donor	renal	
transplant	and	a	T	cell–depleting	induction	regimen	with	alemtu‐
zumab.	The	nocardia	 infection	 resolved	after	 imipenem	and	oral	
sulfamethoxazole/trimethoprim.
As	of	the	data	cutoff	date	of	March	10,	2017,	the	8	patients	who	
received	a	transplant	on	study	displayed	a	median	eGFR15	of	76	mL/
min/1.73 m2,	ranging	from	43	to	104	mL/min/1.73	m2	by	week	12	after	
transplant,	and	there	were	no	signs	of	antibody‐mediated	rejection.
Whereas	serum	IgA	and	IgM	levels	slightly	decreased	from	base‐
line	 to	 week	 12	 to	 a	mean	 (median)	 of	 96.6%	 (95.6%)	 and	 91.7%	
(87.9%),	 respectively,	 serum	 IgG	 increased	 to	 a	 mean	 (median)	
of	114%	 (111%).	From	baseline	 to	week	24,	 IgA,	 IgM,	and	 IgG	de‐
creased	 to	a	mean	 (median)	of	93.3%	 (86.5%),	94.0%	 (68.2%),	 and	
88.0%	(88.6%),	respectively.	Changes	in	cohort	1	and	cohort	2	were	
comparable.	No	correlation	between	the	onset	of	infection	and	im‐
munoglobulin	levels	was	observed.
Vaccination	titers	were	stable	throughout	the	study.	There	were	
no	changes	 in	 serostatus	of	antibodies	 to	mumps,	 rubella,	or	vari‐
cella‐zoster.	Antipneumococcal	capsular	polysaccharide	and	antitet‐
anus	toxoid	antibody	titers	fluctuated,	but	the	median	concentration	
did	 not	 change	 between	 screening	 and	week	 24	 and	 all	 titers	 re‐
mained	in	the	protective	range.
3.3 | Pharmacodynamic analyses
3.3.1 | Peripheral B cells
By	week	3	after	first	obinutuzumab	dose,	60%	and	100%	of	patients	
in	cohorts	1	and	2	(with	reported	results),	respectively,	had	CD19+ 
B	cells	depleted	to	<0.441	cells/μL.	By	week	24,	80%	of	patients	in	
cohort	1	had	detectable	CD19+	B	cell	levels,	and	in	cohort	2,	90%	of	
patients	with	reported	results	still	had	fully	depleted	CD19+	B	cells	
(Figure	2).	A	patient	 in	cohort	2	had	 rapid	 repopulation	of	B	cells.	
Subsequent	analysis	revealed	reduced	obinutuzumab	exposure	and	
the	presence	of	antidrug	antibodies	(data	not	shown).	Obinutuzumab	
appeared	to	reduce	peripheral	CD4+	and	CD8+	T	cells	on	average	by	
15%‐36%	(Figure	S2).
3.3.2 | CD19+ B cells in lymph nodes
In	patients	who	received	a	transplant,	the	level	of	CD19+	B	cells	in	re‐
troperitoneal	lymph	nodes	procured	at	time	of	transplant	appeared	
reduced	 in	 the	 majority	 (5/7)	 relative	 to	 observational	 compara‐
tor	 cohorts	 of	 peritransplant	 patients	who	 had	 not	 been	 exposed	
to	obinutuzumab	 (Data	S1;	 Figure	3).	 The	2	patients	whose	B	 cell	
percentages	in	lymph	nodes	were	not	reduced	relative	to	nonstudy	
 Cohort 1 (n = 5) Cohort 2 (n = 20)
All patients 
(N = 25)
Age,	median	(range),	y 46	(34‐54) 51	(29‐65) 48	(29‐65)
Female,	n	(%) 4	(80) 18	(90) 22	(88)
Race,	n	(%)
White 2	(40) 14	(70) 16	(64)
Black/African	American 3	(60) 4	(20) 7	(28)
Asian 0 2	(10) 2	(8)
Primary	ESRD	diagnosis,	n	(%)
Hypertension 1	(20) 0 1	(4)
Cystic	disease 2	(40) 7	(35) 9	(36)
Glomerulonephritis 0 4	(20) 4	(16)
Diabetes 0 6	(30) 6	(24)
Other 2	(40) 3	(15) 5	(20)
Years	on	waitlist,	median	
(range)
8.0	(3.2‐12) 4.9	(0.63‐12) 5.3	(0.63‐12)
Immunizing	events,	n	(%)
Pregnancy	[para] 4	(80)	[1‐2] 18	(90)	[1‐8] 22	(84)	[1‐8]
Blood	transfusion 3	(60) 13	(65) 16	(64)
Prior	transplant 3	(60) 3	(15) 6	(24)
CPRA,	median	(range),	%a 99.95	(72.29‐99.96) 91.77	(49.44‐99.99) 94.51 
(49.44‐99.99)
No.	of	UAs,	median	
(range)
33	(7‐56) 24	(2‐67) 26.5	(2‐67)
Abbreviations:	CPRA,	calculated	panel	reactive	antibody	level;	ESRD,	end‐stage	renal	disease;	
para,	number	of	pregnancies	reaching	viable	gestational	age;	UA,	unacceptable	antigen.
aCPRA	data	presented	here	are	those	generated	at	a	central	laboratory,	not	the	local	site	 
laboratories.	
TA B L E  1  Baseline	patient	
demographics	and	clinical	characteristics
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comparator	nodes	were	 fully	depleted	 in	blood	by	high‐sensitivity	
flow	cytometry	at	the	time	of	transplant.
3.3.3 | Anti‐HLA antibody profile
Mean	changes	in	MFI	over	all	alleles	were	modest	for	most	patients	
and	 largely	within	 the	assay	variability	margin.	Post‐hoc	 individual	
patient	bootstrapping	analyses	 revealed	that	3	patients	 (all	cohort	
2)	had	reductions	in	overall	mean	MFI	values	by	≥25%	and	that	no	
patient	had	 increase	of	≥25%	 (Figure	4).	Mean	MFI	posttreatment	
changes	 from	baseline	 ranged	 from	−17.1%	 to	−3.24%	 in	 cohort	1	
and	from	−31.4%	to	20.6%	in	cohort	2	(Figure	4,	exemplary	patient	
profiles	in	the	Figure	S3).	Only	four	patients	had	posttreatment	MFI	
increases	or	decreases	 from	baseline	of	>50%	 in	 a	 subset	of	 their	
HLA	reactivities	 (data	not	shown),	a	 level	of	change	thought	to	be	
significant	 relative	 to	 assay	 variability.16	 Two	 of	 these	 patients	 (1	
each	in	cohorts	1	and	2)	had	decreases	of	>50%	from	baseline,	con‐
sistent	with	desensitization,	 in	2	of	52	alleles	and	24	of	58	alleles,	
respectively.	The	patient	from	cohort	2	with	a	significant	reduction	
in	24	of	58	alleles	exhibited	a	parallel	pronounced	MFI	 increase	 in	
another	18	alleles	(Figure	4	inset).	Two	patients	in	cohort	2	had	un‐
expected	MFI	increases	>50%	in	1	of	38	alleles	and	5	of	51	alleles,	
respectively.	According	to	results	with	corresponding	diluted	base‐
line	 samples,	MFI	 increases	were	 not	 due	 to	 the	 attenuation	 of	 a	
prozone	 effect,	 except	 for	 possibly	 in	 1	 patient	 in	whom	baseline	
MFI	signals	for	8	of	58	alleles	indeed	displayed	a	hook	effect	upon	
dilution	 (Data	S1).	There	were	no	obvious	sensitizing	or	 infectious	
events	that	coincided	with	the	signal	increase	in	these	6	patients.
3.3.4 | Unacceptable antigens and CPRA over time
The	number	of	UA	ranged	from	2	to	67	(median,	27)	per	patient	at	
baseline.	 From	 baseline	 to	 a	 median	 posttreatment	 time	 point	 of	
24	weeks,	14	of	24	patients	had	a	numerical	decrease	in	UA	(mean,	
−4.5),	 whereas	 2	 of	 24	 had	 an	 increase	 (mean,	 +2.5;	 Figure	 5A).	
Of	the	16	patients	with	changes	in	the	number	of	UAs,	only	4	had	
changes	that	resulted	from	a	significant	MFI	change	of	>50%	on	top	
of	crossing	the	threshold;	2	patients	had	increases	(+2	and	+3)	and	2	
had	decreases	in	the	number	of	UAs	(−1	and	−5)	(Figure	5B).
Of	 the	24	patients	 analyzed,	 changes	 in	UA	 (defined	by	cross‐
ing	MFI	threshold	only)	resulted	in	CPRA	reductions	in	12	patients	
and	increases	in	2	patients	(Figure	5C).	Mean	change	in	CPRA	was	
−0.98%	(range,	−18.8%	to	+10.4%).	When	posttreatment	CPRA	ac‐
counted	for	changes	in	UA	that	were	additionally	accompanied	by	a	
minimum	50%	MFI	change	from	baseline,	2	of	the	24	patients	had	in‐
creases	and	2	had	decreases	in	CPRA,	with	a	mean	change	of	0.15%	
(range,	−1.31%	to	+5.11%)	(Figure	5D).
3.4 | On‐study kidney transplants
At	 the	 time	of	 the	primary	analysis,	8	of	 the	25	patients	 (cohort	
1,	n	=	1;	cohort	2,	n	=	7)	had	 received	a	deceased‐donor	kidney	
Patient no. Obinutuzumab doses
Time from last obinutuzumab 
dose to SAE onset, wk
SAE, preferred 
term
102 1 4 Pneumonia
17 Device‐related	
infection
104 1 34 Diverticulitis
110	(Tx) 3 8 Pneumonia	
(posttransplant)
  9 Nocardiosis	
(posttransplant)
112 2 6 Sepsis
117	(Tx) 3 5 Incision‐site	
infection	
(posttransplant)
118	(Tx)a 1 6 Postoperative	
wound	
infection	
(posttransplant)
121 2 5 Escherichia coli 
UTI
123 3 6 Angina	pectoris
125 2 4 Peritonitis
Abbreviations:	SAE,	serious	adverse	event;	Tx,	received	transplant;	UTI,	urinary	tract	infection.
aThis	patient	was	withdrawn,	followed	up	only	for	safety,	and	not	considered	in	the	desensitization	
analysis.	
TA B L E  2  Serious	adverse	events
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transplant,	 occurring	 at	week	1	 (in	 a	 patient	 from	cohort	2	who	
was	withdrawn	from	study	treatment	and	not	considered	for	ex‐
ploratory	efficacy	analysis)	and	at	weeks	15,	16,	19,	21,	21,	22,	and	
40.	The	8	patients	who	received	a	transplant	up	until	the	time	of	
the	primary	analysis	had	baseline	characteristics	similar	to	those	
in	patients	who	had	not	received	a	transplant,	including	ESRD	his‐
tory	and	level	of	sensitization.	Two	of	the	8	transplanted	patients	
had	 a	 prior	 kidney	 transplant,	 consistent	with	 the	 proportion	 of	
patients	with	prior	transplants	 in	the	study	 (6/25).	 In	addition	to	
obinutuzumab,	 all	 patients	 received	 a	 center‐specific	 standard‐
of‐care	 multidrug	 immunosuppressive	 induction	 regimen:	 my‐
cophenolic	acid	or	its	prodrug	mycophenolate	mofetil,	tacrolimus,	
and	 corticosteroids.	 Five	 patients	 received	 thymoglobulin	 and	 3	
patients	 received	 alemtuzumab;	 2	 patients	 additionally	 received	
high‐dose	 IVIG.	 None	 of	 the	 mismatched	 donor	 antigens	 were	
listed	as	UAs	by	the	patient's	program.	Two	of	7	patients	displayed	
donor‐specific	 anti‐HLA	 antibodies	 (DSAs)	 at	 time	 of	 transplant	
based	on	central	laboratory	SAB	results:	anti‐A24	at	MFI	4700	in	1	
patient	from	cohort	2	(reduced	from	13	860	at	baseline)	and	anti‐
DR8	at	MFI	2350	in	another	patient	from	cohort	1	(reduced	from	
3030	at	baseline).	Virtual	crossmatch	was	negative	in	the	8	trans‐
planted	patients	based	on	center‐specific	criteria.	Flow	cytomet‐
ric	 crossmatch	 tests	 against	donor	B	 cells	 using	 serum	collected	
immediately	before	kidney	transplant	was	positive	for	3	of	the	6	
evaluable	patients	(2	of	these	3	were	the	patients	with	preexisting	
DSAs),	equivocal	for	1,	and	negative	for	2;	the	corresponding	flow	
cytometric	 crossmatch	 against	 donor	 T	 cells	was	 negative	 for	 7	
of	7	evaluable	patients.	All	those	crossmatches	were	done	locally	
in	 presence	 of	 pronase	 to	 attenuate	 potential	 interference	 from	
residual	anti‐CD20	therapeutic	antibody	and	were	assessed	based	
on	center‐defined	thresholds.
3.5 | Pharmacokinetic analyses
PK	data	were	available	 from	all	25	patients	using	 limited	PK	sam‐
pling.	Obinutuzumab	serum	concentration	data	were	analyzed	using	
nonlinear	mixed	effect	modeling.17	The	concentration‐time	course	
of	obinutuzumab	was	well	described	by	a	linear	2‐compartment	PK	
model	with	time‐dependent	clearance.	Clearance	and	volume	of	dis‐
tribution	parameters	 increased	with	body	weight	and	were	higher	
in	male	patients,	although	data	from	only	3	male	patients	were	in‐
cluded;	body	weight	and	gender	are	known	to	affect	obinutuzumab	
PK	in	hematological	 indications.18	Main	PK	parameters	following	2	
doses	of	1000‐mg	obinutuzumab	(cohort	2)	are	shown	in	Table	3.
In	the	population	PK	model	in	patients	with	ESRD,	after	the	last	dose	
in cohort 2 the estimated median Cmax	was	409	μg/mL	and	AUC168d	was	
11	981	μg	×	day/mL.	Following	IV	administration,	the	median	volume	of	
distribution	at	steady	state	was	3.77	L,	which	approximates	total	blood	
volume,	indicating	that	distribution	was	largely	restricted	to	plasma	and	
interstitial	 fluid.	 The	 clearance	 of	 obinutuzumab	 was	 approximately	
0.18,	0.13,	and	0.09	L/d	at	time	0,	month	6,	and	month	12,	respectively.	
The	1	male	patient	in	cohort	2	with	antidrug	antibody	who	had	low	ex‐
posure	had	rapid	recovery	of	peripheral	B	cells	(Figure	2).
4  | DISCUSSION
At	the	time	this	study	was	designed,	highly	sensitized	patients	with	
ESRD	made	up	30%	of	the	kidney	transplant	waitlist.	These	patients	
have	longer	wait	times	for	a	suitable	donor	graft	and	inferior	long‐
term	outcomes	following	transplant	than	patients	who	are	not	sensi‐
tized.4‐6,19	With	no	approved	pharmacological	therapy	to	reduce	the	
degree	of	sensitization	before	transplant,	new	approaches	for	effec‐
tive	desensitization	to	control	HLA‐specific	alloantibody	production	
remain	an	unmet	medical	need.	This	study	assessed	the	safety,	PK/
PD,	and	exploratory	efficacy	of	obinutuzumab/IVIG	in	highly	sensi‐
tized	patients	with	ESRD.
This	is	the	first	study	assessing	obinutuzumab	outside	of	oncol‐
ogy.	No	new	 safety	 signals	were	 identified	 in	 patients	with	 ESRD	
awaiting	 renal	 transplant.	 The	 most	 common	 AEs	 were	 IRRs.	 In	
F I G U R E  2  CD19+	peripheral	B	cell	counts	in	patients	from	
cohort	1	and	cohort	2	during	the	desensitization	phase.	Cell	counts	
are	given	in	number	of	cells	per	μL	as	a	function	of	study	days.	The	
lower	limit	of	quantification	of	the	high‐sensitivity	flow	cytometry	
assay	was	0.441	cells/μL	and	is	indicated	with	a	dashed	line.	Traces	
for	the	2	patients	with	detectable	antidrug	antibodies	are	marked	
with	an	asterisk
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contrast	 to	 previous	 experience	with	 obinutuzumab	 in	 oncology—
where	 20%	 of	 patients	 with	 CLL	 experienced	 grade	 3	 or	 4	 IRRs,	
frequently	leading	to	treatment	modification	or	discontinuation—all	
IRRs	in	this	study	were	mild	to	moderate	and	none	resulted	in	treat‐
ment	withdrawal	or	incomplete	drug	administration.
In	patients	with	B	cell	malignancies,	a	2‐compartment	PK	model	
with	 linear	 and	 time‐dependent	 clearance	 components	 accurately	
described	 the	 concentration‐time	 course	 of	 obinutuzumab,	 with	
steady‐state	 PK	 parameter	 values	 typical	 of	 monoclonal	 antibod‐
ies.18	 In	 those	 patients,	 time‐dependent	 clearance	 components	
reflected	 the	 depletion	 of	 the	 target	 or	 changes	 in	 the	 target	 ex‐
pression	 levels	with	 time.	 In	patients	with	ESRD,	 the	 clearance	of	
obinutuzumab	 was	 at	 the	 lower	 end	 of	 the	 range	 known	 for	 IgG	
clearance;20	why	obinutuzumab	clearance	continued	to	depend	on	
time	in	these	patients	remains	unclear.	The	volume	of	distribution	at	
steady‐state	approximated	 total	blood	volume,	 indicating	distribu‐
tion	was	largely	restricted	to	plasma	and	interstitial	fluid.
Based	 on	 high‐sensitivity	 flow	 cytometry,	 peripheral	 blood	
CD19+	B	cell	depletion	after	one	1000‐mg	obinutuzumab	dose	was	
rapid	 and	 strong,	with	 repopulation	by	24	weeks.	B	 cell	 depletion	
after	2	obinutuzumab	doses	appeared	longer	lasting,	with	the	major‐
ity	of	patients	still	fully	depleted	at	week	24.	CD19+	B	cells	in	lymph	
nodes	 collected	 at	 the	 time	 of	 transplant	 appeared	 to	 also	 be	 ef‐
fectively	reduced	by	obinutuzumab/IVIG	in	the	majority	of	patients	
tested,	including	memory	B	cells	and	plasmablasts	(Looney	et	al,	in	
preparation).	Future	desensitization	studies	with	obinutuzumab	may	
warrant	 initial	 treatment	with	2	doses	of	obinutuzumab	to	reliably	
deplete	B	cells	over	several	months.
Rituximab	 has	 had	 limited	 success	 in	 reducing	 anti‐HLA	 anti‐
body	levels	in	patients	with	ESRD,	with	some	uncontrolled	studies	
showing	no	effect,8‐12	possibly	due	to	incomplete	tissue	B	cell	deple‐
tion.8,11‐13	The	current	study	was	carried	out	based	on	the	improved	
B	cell	depletion	observed	in	blood	and	secondary	lymphoid	organs	
with	 obinutuzumab	 compared	 with	 rituximab.13,14	 Obinutuzumab	
resulted	 in	 extensive	peripheral	 blood	 and	 tissue	B	 cell	 depletion;	
however,	anti‐HLA	antibody	reductions	were	inconsistent	and	lim‐
ited.	Although	a	 few	patients	did	display	pronounced	 reduction	 in	
some	anti‐HLA	reactivities,	the	results	of	this	study	do	not	suggest	
a	 clinically	 meaningful	 desensitizing	 effect	 across	 most	 patients.	
The	fact	that	depletion	of	CD20+	B	cells	alone	does	not	significantly	
affect	HLA	antibody	production	 indicates	that	HLA	antibodies	are	
produced	by	CD20−,	mature,	 long‐lived	plasma	cells.	These	plasma	
cells	may	not	depend	on	 constant	 replenishment	 from	a	CD20+	B	
cell	population	but	rather	may	exist	for	the	remainder	of	the	host's	
life,	 only	 gradually	 outcompeted	 by	 newly	 produced	 plasma	 cells.	
Consistent	with	this,	vaccination	Ig	titers	were	also	not	significantly	
affected	by	obinutuzumab.
Based	on	these	 findings,	one	may	expect	plasma‐cell	 targeting	
to	 have	 greater	 effects	 on	 the	 reduction	 of	 anti‐HLA	 antibody	 ti‐
ters.	However,	despite	its	ability	to	significantly	deplete	bone	mar‐
row	plasma	cells,	treatment	with	proteasome	inhibitors	(PI)	results	in	
variable	reductions	in	anti‐HLA	antibodies	in	transplant	patients	and	
autoantibodies	in	patients	with	autoimmune	disease,21‐24	likely	due	
to	 the	 frequent	 occurrence	 of	 rebound	 in	 antibody	 production.25 
Potential	mechanisms	underlying	these	observations	have	been	re‐
cently	described	 in	Rhesus	macaques	by	Kwun	et	al26	and	suggest	
a	compensatory	increase	in	memory	B	cells	following	PI	treatment	
that	may	then	replenish	plasma	cells	and	help	maintain	anti‐HLA	al‐
loantibody	levels.	Alternatively,	niche‐resident	plasma	cells	may	ex‐
hibit	varying	degrees	of	PI	resistance.
Targeting	 long‐lived	 plasma	 cells	while	 also	 inhibiting	 their	 re‐
newal	 via	 effective	 B	 cell	 depletion	 with	 obinutuzumab	may	 rep‐
resent	 a	 promising	 avenue	 forward.	 Newer‐generation	 PIs,	 eg	
carfilzomib,	 may	 provide	 improved	 tolerability	 and	 effectiveness	
F I G U R E  3  CD19+	B	cell	frequency	
in	peritoneal	lymph	nodes	of	patients	
who	received	a	transplant	(7	patients,	13	
nodes)
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over	 bortezomib.27,28	 Alternatively,	 future	 therapeutic	 regimens	
could	combine	obinutuzumab	with	antibodies	targeting	plasma‐cell	
survival	 factors	 like	 IL‐6,	 B	 cell	 activating	 factor	 (BAFF),	 and/or	 a	
proliferation‐inducing	 ligand	 (APRIL).29	 The	benefit	of	 suppressing	
anti‐HLA	 alloantibodies	 via	 sustained	 plasma‐cell	 depletion	 with	
combination	therapy	will	need	to	be	weighed	against	the	safety	risk	
of	depleting	protective	humoral	response	and	vaccinations.
HLA	alloantibodies	were	assessed	 in	a	central	 laboratory	using	
a	 state‐of‐the‐art	 fluorescence‐based	 SAB‐based	 assay.	 In	 con‐
trast,	 earlier	 positive	 studies	 with	 rituximab/IVIG	 or	 IVIG	 alone	
had	 employed	 a	 cytotoxic	 lymphocyte	 panel	 assay	 and	 suggested	
more	meaningful	and	consistent	desensitization	based	on	PRA.7,30 
Although	antibody	strength	as	reflected	in	SAB	MFI	signals	is	typi‐
cally	considered	a	prerequisite	for	identifying	clinically	relevant	anti‐
HLA	alloantibodies,	assessing	desensitization	based	on	all	positive	
MFI	 reactivities	 may	 neglect	 a	 clinically	 meaningful	 desensitizing	
effect	on	specific	alloantigens.	The	ideal	endpoint	in	desensitization	
remains	to	be	defined	because	each	technique	for	evaluation	of	effi‐
cacy	presents	challenges	and	opportunities;	this	difficulty	in	finding	
an appropriate endpoint is common in transplant.31 The main lim‐
itations	 of	 this	 study	 are	 the	 lack	 of	 an	 IVIG	 control	 arm	 and	 the	
small	study	size,	which	do	not	allow	for	a	more	clinically	meaningful	
endpoint,	eg	the	rate	of	transplantation.	The	limited	follow‐up	at	the	
time	of	the	data	cutoff	limits	conclusions	on	longer‐term	safety.
By	the	data	cutoff	of	March	10,	2017,	8	patients	had	received	
a	 transplant	 (1	who	 received	 the	 transplant	 at	week	 1	was	with‐
drawn,	only	 followed	up	 for	 safety,	 and	not	 considered	 in	 the	ex‐
ploratory	efficacy	or	tissue	B	cell	analyses).	For	the	remaining	7,	the	
flow‐cytometry–mediated	 (FCM)	 crossmatch	 experiments	 did	 not	
result	 in	any	positive	T	cell	crossmatch	but	did	result	 in	a	positive	
B	cell	crossmatch	for	3	patients.	Of	those	3	patients,	2	had	B	cell	
crossmatch	based	on	pre‐treatment	baseline	samples	that	were	al‐
ready	 positive,	 and	 1	 had	B	 cell	 crossmatch	 converted	 from	 neg‐
ative	at	baseline	 to	positive	at	 the	 time	of	 transplant.	Although	B	
F I G U R E  4  Mean	percent	reduction	in	MFI	and	95%	CIs	from	baseline	to	week	24	(filled	circles)	or	last	valid	MFI	measurement	(open	
circles);	limited	to	alleles	with	MFI	>	3000	at	any	time	point	and	baseline	or	posttreatment	MFI	>	500.	Marker	size	is	proportional	to	the	
number	of	alleles	per	patient.	Mean	and	95%	CIs	were	calculated	using	bootstrapping	with	bias‐corrected	CI.	Patients	who	have	received	a	
transplant	are	encircled	in	green;	patients	identified	as	biological	responders	by	the	DASP	are	boxed.	Abbreviations:	CI,	confidence	interval;	
DASP,	desensitization	assessment	scientific	panel;	MFI,	mean	fluorescence	intensity
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cell	crossmatch	was	performed	after	treatment	with	pronase,	a	false	
negative	 result	 through	 residual	 anti‐CD20	antibody	 in	 recipients’	
serum	cannot	completely	be	ruled	out.	It	is	difficult	to	conclusively	
determine	 the	 impact	of	obinutuzumab/IVIG	on	 the	 rate	of	 trans‐
plant	owing	to	the	contemporary	implementation	of	the	new	Kidney	
Allocation	System,	which	prioritizes	allocation	 to	highly	sensitized	
patients—and	may	 alter	 the	 need	 for	 desensitization	 treatment	 in	
deceased‐donor	 transplant	 recipients	 in	 the	 United	 States.	 B	 cell	
depletion	 therapy	may	 improve	 posttransplant	 outcomes	 by	 con‐
trolling	amnestic	DSA	expansion	and	preventing	antibody‐mediated	
F I G U R E  5  Change	in	the	number	of	UAs	(A,	B)	and	CPRA	score	(C,	D)	from	baseline	to	week	24	or	last	valid	MFI	measurement.	For	UAs	
and	CPRA	presented	in	panels	B	and	D,	change	in	acceptability	of	a	given	antigen	needed	not	only	to	surpass	the	MFI	threshold	of	3000	but	
also	display	a	robust	change	in	MFI	of	50%.	Abbreviations:	CFB,	change	from	baseline;	CPRA,	calculated	panel	reactive	antibody;	MFI,	mean	
fluorescence	intensity;	UA,	unacceptable	antigen
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rejection.32,33	In	our	study,	obinutuzumab/IVIG	resulted	in	profound	
and	lasting	depletion	of	peripheral	CD19+	B	cells.	The	follow‐up	of	
patients	who	received	transplants	will	allow	assessment	of	any	po‐
tential	prevention	of	humoral	rejection	in	this	high‐risk	population.
In	 summary,	 obinutuzumab	was	well	 tolerated	 in	 patients	with	
ESRD	awaiting	renal	transplant.	Although	obinutuzumab	resulted	in	
profound	peripheral	blood	B	cell	depletion	and	appeared	to	reduce	
B	cells	substantially	in	lymph	nodes,	the	effect	of	obinutuzumab	on	
anti‐HLA	alloantibodies,	UAs,	and	CPRA	was	limited	and	inconsistent.
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Parameter
Time after first dose
Initial time (Time = 0) Month 6 Month 12
CL,	L/d
Geometric 
mean	(CV%)
0.176	(0.312) 0.126	(0.312) 0.0895	(0.312)
Median	(range) 0.176	(0.0752‐0.292) 0.126	(0.0536‐0.208) 0.0895	(0.0382‐0.148)
Effective	half‐life,	day
Geometric 
mean	(CV%)
14.3	(0.2) 20.1	(0.2) 28.2	(0.2)
Median	(range) 14.8	(9.3‐19.8) 20.8	(13.0‐27.8) 29.2	(18.3‐39.1)
Cmax,	μg/mL
Geometric 
mean	(CV%)
419.9	(0.23)
Median	(range) 408.5	(278.6‐807.3)
Ctrough,	μg/mL
Geometric 
mean	(CV%)
0.7	(1.37)
Median	(range) 0.9	(0.0‐5.8)
AUC168d,	μg	×	d/mL
Geometric 
mean	(CV%)
11	958	(0.32)
Median	(range) 11	981	(7147‐28	229)
Note: CV	was	computed	as	the	standard	deviation	of	the	log‐transformed	data.
Abbreviations:	AUC168d,	cumulative	area	under	the	concentration‐time	curve	over	168	d;	CL,	
clearance	of	obinutuzumab;	Cmax,	maximum	observed	serum	concentration	after	second	dose	of	
obinutuzumab;	Ctrough,	minimum	serum	concentration	(before	dose	on	day	168);	CV,	coefficient	of	
variation;	PK,	pharmacokinetic.
TA B L E  3  Predicted	PK	parameters	in	
patients	from	cohort	2
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